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Carriers of Rare Missense Variants in IFIH1
Are Protected from Psoriasis
Yonghong Li1, Wilson Liao2, Michele Cargill1,6, Monica Chang1, Nori Matsunami3, Bing-Jian Feng4,
Annie Poon2, Kristina P. Callis-Duffin4, Joseph J. Catanese1, Anne M. Bowcock5, Mark F. Leppert3,
Pui-Yan Kwok2, Gerald G. Krueger4 and Ann B. Begovich1,7
Testing ofB25,000 putative functional single-nucleotide polymorphisms (SNPs) across the human genome in a
genetic association study has identified three psoriasis genes, IL12B, IL23R, and IL13. We now report evidence
for the association of psoriasis risk with missense SNPs in the interferon induced with helicase C domain 1 gene
(IFIH1). The rare alleles of two independent SNPs were associated with decreased risk of psoriasis—rs35667974
(Ile923Val): odds ratio (OR) for minor allele carriers is 0.43, P¼ 2.36 105 (2,098 cases vs. 1,748 controls); and
rs10930046 (His460Arg): OR for minor allele carriers is 0.51, P¼ 6.47 104 (2,098 cases vs. 1,744 controls).
Compared to noncarriers, carriers of the 923Val and/or 460Arg variants were protected from psoriasis (OR¼ 0.46,
P¼ 5.56 108). To our knowledge, these results suggest that IFIH1 is a previously unreported psoriasis gene.
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INTRODUCTION
Psoriasis is a common, chronic, T-cell-mediated inflamma-
tory disease of the skin (Nestle et al., 2009) affecting 2–3%
of whites of European descent but fewer Asians and Africans
(Campalani and Barker, 2005). It is considered a multi-
factorial, complex disease involving both genetic and
environmental factors (Bowcock and Krueger, 2005; Smith
et al., 2009). Genetic contribution to the disease is shown by
increased concordance in monozygotic compared to dizy-
gotic twins (72% vs. 15–23%, respectively, for northern
Europeans) and the observation that upward of 71% of
patients with childhood psoriasis has a positive family history
(Bowcock and Krueger, 2005). Indeed, the HLA variant HLA-
Cw*0602 strongly predisposes individuals to psoriasis (Nair
et al., 2006; Fan et al., 2008), and multiple single-nucleotide
polymorphisms (SNPs) in at least seven genes, which include
IL12B, IL13, IL23R, STAT2/IL23A, TNFAIP3, TNIP1, and LCE,
have been convincingly associated with psoriasis risk (Cargill
et al., 2007; Chang et al., 2008; Liu et al., 2008; Nair et al.,
2009; Zhang et al., 2009; de Cid et al., 2009). Variants in
b-defensin, CDKAL1, and other genes may also affect risk of
psoriasis (Lesueur et al., 2007; Capon et al., 2008; Hollox
et al., 2008; Wolf et al., 2008; Li et al., 2009). However,
these variants do not fully account for the genetic contribu-
tion to psoriasis, underscoring the necessity of further search
for other genetic variants.
RESULTS
We recently conducted a large-scale genetic association study
testing 25,215 putative functional SNPs across the genome in
three independent white psoriasis case–control sample sets. On
the basis of these data, we reported results that validated IL12B
and provided the first evidence for IL23R and IL13 as psoriasis
risk genes (Cargill et al., 2007; Chang et al., 2008).
To continue the search for psoriasis genes, we prioritized
the remaining markers from our genetic study for additional
genotyping and association testing. Excluding markers in the
HLA, IL12B, IL23R, and IL13 loci, we individually genotyped
and analyzed 337 autosomal markers in one or more of the
three sample sets (all markers had Hardy–Weinberg equili-
brium P40.001 in controls). An association test showed that
113 markers were associated with psoriasis risk (allelic
Po0.05 in all samples tested) (Supplementary Table S1
online); these markers include one SNP in PADI4, which is
involved in the genetics of rheumatoid arthritis (Suzuki et al.,
2003), and one in FNDC1, which is highly expressed in the
epidermis of psoriatic skin but barely detectable in normal
skin (Anderegg et al., 2005).
The most significant marker was rs35667974 in the IFIH1
gene on chromosome 2 (allelic P¼1.74 105; 1,436 cases/
1,379 controls). Another SNP in IFIH1, rs10930046, was also
associated with psoriasis risk (allelic P¼0.0055). Further
testing of these two polymorphisms in a fourth sample set
(667 cases/371 controls) replicated rs10930046 (replication
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allelic P¼ 0.031, Supplementary Table S1 online), and the
odds ratio (OR) of rs35667974 was in the same direction as in
the other three sample sets (replication allelic P¼0.42,
Supplementary Table S1 online). Both markers are missense
polymorphisms, resulting in Ile923Val and His460Arg
variants, respectively, in the IFIH1 polypeptide. The minor
allele frequencies of both the 923Val and 460Arg variants
were low, 2.2 and 2.1%, respectively, in the control
population. Because of the low allele frequency, very few
individuals carried two copies of either of the protective
(minor) variants; therefore, testing the carrier status of the
protective alleles did not substantially alter the association
results (Table 1). Compared with noncarriers, carriers of
923Val or 460Arg variant were protected from psoriasis.
These two IFIH1 markers were not correlated with each
other (r2¼0.001 in the control samples). As shown in Table 2,
only one case and two controls carried both the rare variants.
Regression analyses showed that both markers remained
significant when adjusted for the other (adjusted Po0.05),
suggesting that the two rare missense variants independently
protected from psoriasis. Because of these findings, we
further tested the combined effect of these two variants on
psoriasis risk. Compared with noncarriers (i.e., individuals
homozygous for both the 460His and 923Ile variants of the
IFIH1 polypeptide), carriers of the protective variants 460Arg
and/or 923Val were significantly associated with lower risk of
psoriasis (OR¼ 0.46, P¼ 5.56108 in all samples com-
bined, Breslow–Day P¼0.11 for OR heterogeneity). Carriers
with at least one protective allele (460Arg, 923Val, or both)
were common, comprising 8.1% of the combined controls
and 3.9% of the combined patient samples.
DISCUSSION
The above results suggest that missense variants in IFIH1
modulate risk of psoriasis in the white, North American
population. The observed statistical evidence are at the level
of P¼ 2.36105, 6.47104, and 5.56108 for
rs35667974 (Ile923Val), rs10930046 (His460Arg), and both
SNPs combined, respectively. In the context of our study that
tested B25,000 putative functional SNPs, the carrier
Table 1. Association of missense variants in IFIH1 with psoriasis
Count2 Carrier freq3 CC+CT vs. TT4
RS number Variation1 Samples CC CT TT Sum CC+CT OR (95% CI) P-value
rs35667974 Ile923Val Case 3 37 2,058 2,098 1.91% 0.43 (0.29–0.64) 2.36105
Control 2 72 1,674 1,748 4.23%
rs10930046 His460Arg Case 3 39 2,056 2,098 2.00% 0.51 (0.35–0.76) 6.47104
Control 4 65 1,675 1,744 3.96%
Abbreviations: CI, confidence interval; OR, odds ratio.
1C allele corresponds to 923Val and 460Arg variants.
2HWE P40.05 (exact test) in controls of individual sample sets for both SNPs.
3Frequency of the carriers of the protective allele.
4Dominant model, adjusted for sample set; test of OR heterogeneity P40.05 among sample sets.
Table 2. Association of psoriasis with carriers of the IFIH1 460Arg and/or 923Val variants
IFIH1 variant2 Count (frequency)
Protective alleles1 Residue 460 Residue 923 Case Control OR (95% CI) P-value
Carriers
Subgroup Arg Ile 39 (1.86%) 72 (4.13%)
His Val 41 (1.96%) 67 (3.85%)
Arg Val 1 (0.05%) 2 (0.11%)
Combined 81 (3.87%) 141 (8.09%)
Noncarriers His Ile 2,011 (96.13%) 1,601 (91.91%)
Carriers vs. noncarriers3 0.46 (0.35–0.61) 5.56108
Abbreviations: CI, confidence interval; OR, odds ratio.
1Carriers of protective IFIH1 alleles have at least one copy of the arginine residue at position 460 or a valine residue at position 923. Noncarriers are
homozygous for the histidine residue at position 460 and the isoleucine residue at position 923.
2Protective alleles in boldface.
3w2-Test, adjusted for sample set.
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association of both SNPs with psoriasis remains significant
when adjusted for multiple testing (Bonferroni corrected
P¼0.0014), suggesting that variants in IFIH1 are genuinely
associated with psoriasis risk.
Pleiotropic effect of IFIH1 in modulating autoimmunity
A role for IFIH1 in the etiology of psoriasis is bolstered by
previously established genetic connections between this gene
and other autoimmune and inflammatory diseases and the
observation that autoimmune and inflammatory diseases
share overlapping genetic factors (Li and Begovich, 2009).
Definitive evidence for a role of IFIH1 in autoimmunity
comes from type 1 diabetes (T1D), where genome-wide
significance is observed for at least two distinct IFIH1 SNPs: a
common missense polymorphism rs1990760 (Ala946Thr; risk
allele frequency¼60% in whites) (Smyth et al., 2006) and the
rare missense polymorphism rs35667974 tested in our study
(Nejentsev et al., 2009). The effect of the common SNP in
T1D is weak (OR¼0.86), whereas that of the rare SNP is
stronger (OR¼0.51). There is also strong evidence for a role
of rs1990760 in systemic lupus erythematosus (Gateva et al.,
2009), inconsistent evidence in multiple sclerosis (Martinez
et al., 2008; Couturier et al., 2009; Enevold et al., 2009) and
Graves’ disease (Sutherland et al., 2007; Penna-Martinez
et al., 2009), and no evidence for celiac disease (Smyth et al.,
2008) or rheumatoid arthritis (Marinou et al., 2007).
SNP rs1990760 has not been tested in our psoriasis
sample sets for technical reasons. Another SNP, rs3747517
(His843Arg), in linkage disequilibrium with rs1990760
(r2¼ 0.61) and associated with T1D (Smyth et al., 2006), is
not significant in the DNA pools of our Sample Set 1 (data not
shown). However, assuming that the frequency of the
rs1990760 risk allele in the unrelated controls is 60% and
an allelic OR of 1.15, as observed in the T1D and systemic
lupus erythematosus studies (Smyth et al., 2006; Gateva
et al., 2009), one would require 1,701 case patients and
1,701 controls to observe an association with disease status
with 80% power at a P-value of 0.05. Thus, our initial
samples may lack sufficient power to determine whether
rs1990760 is associated with psoriasis.
Rare genetic variants and risk of psoriasis
The effect of the IFIH1 923Val variant (minor allele of
rs35667974) on risk of psoriasis and T1D is in the same
direction and of similar magnitude (allelic OR¼ 0.45 (this
study) and 0.51 (Nejentsev et al., 2009)). Carriers of the
protective allele 923Val comprise 4.2% of the control
population, and, when the other rare missense SNP is also
considered, carriers of either of the protective alleles account
for 8.1% of the controls. These observations underscore the
important contribution of rare variants to disease suscept-
ibility of common complex diseases such as psoriasis. They
also have implications in not only further validating IFIH1 as
a psoriasis risk gene but also suggesting variants in this gene
be reevaluated in appropriately powered studies of other
autoimmune diseases. Assuming that the minor allele
frequency of rs35667974 in controls is 2.2% (as observed
in this and the T1D studies) and effect size of 0.50, the
number of samples required to achieve 80% power is
estimated to be 1,080 cases with an equal number of
controls. Interestingly, under the above assumptions, a given
case–control sample set is predicted to have more power to
detect this rare SNP (Ile923Val) with its stronger effect than
the common SNP (Ala946Thr) with its weaker effect. There-
fore, this rare SNP warrants testing in the other autoimmune
studies to further clarify its role in modulating disease risk.
The other psoriasis-associated SNP, rs10930046
(His460Arg), is not associated with T1D (Nejentsev et al.,
2009). It is possible that distinct variants of the same risk
factor may differentially affect individual diseases. Alterna-
tively, this finding may be the result of type I error. We notice
that unlike rs35667974, which has the same frequency in our
controls and the T1D controls, the minor allele frequency of
rs10930046 is somewhat different between our white, North
American controls and the UK T1D controls (2.1 vs. 1.0%).
Therefore, further testing of this marker in other psoriasis
sample sets is required. Interestingly, residue 460 lies in
the helicase ATP-binding domain of the IFIH1 protein,
although it remains to be determined whether a change from
a histidine residue to an arginine residue (BLOSUM62
score¼ 0) affects protein activity.
Biological evidence for a role of IFIH1 in psoriasis
The known biological function of IFIH1 supports a role for
this gene in psoriasis. IFIH1 is an interferon-induced putative
RNA helicase that affects cell growth, differentiation, and
death (Kang et al., 2002; Besch et al., 2009) and has been
implicated in the recognition of RNA viruses (Kato et al.,
2006). Virus infection may be one of the environment factors
that trigger and/or exacerbate psoriasis, and human endo-
genous retroviruses have been detected in psoriatic skins (Fry
and Baker, 2007). In addition, IFIH1 expression is increased
in epidermal cells and tissues from psoriatic plaques
compared to normal controls (Prens et al., 2008); increased
IFIH1 expression may account for some IFIH1 risk variants in
T1D (Liu et al., 2009). Together with these and other biolo-
gical evidence, our genetic results suggest that understanding
how the identified missense variants differentially affect IFIH1
protein function is important, particularly the conserved
923Ile versus 923Val (BLOSUM62 score¼ 3). Elucidation of
their functional differences will provide insights into the role
for IFIH1 in the pathogenesis of psoriasis and may guide the
design of pharmacological interventions either directly or
indirectly targeting IFIH1 for the treatment of psoriasis and
other autoimmune and inflammatory diseases.
MATERIALS AND METHODS
Samples and strategy
Samples from dermatologist-confirmed psoriasis patients and normal
healthy controls were collected from the University of Utah (Sample
Set 1: 467 cases and 460 controls), from the Genomics Collaborative
Division of SeraCare Life Sciences (Sample Set 2: 498 cases and 498
controls), and from Genomics Collaborative and BioCollections
Worldwide (Sample Set 3: 483 cases and 427 controls). All
individuals were white, North Americans and were 18 years or
older at the time they were enrolled in the sample collections. A
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detailed description of clinical and demographic information can be
found in a previous publication (Cargill et al., 2007). A fourth sample
set contained 667 cases and 371 controls: psoriasis cases were
Caucasians with plaque-type psoriasis recruited at the University of
California, San Francisco and Washington University, St Louis.
Controls were healthy Caucasians with no history of autoimmune or
inflammatory disease recruited from San Francisco. The female/male
ratio was 1:1, and for cases the mean age of disease onset was 27
years with a standard deviation of 17. All protocols were approved
by national and/or local institutional review boards, informed
written consent was obtained from all subjects, and the study was
conducted according to the Declaration of Helsinki Principles.
The initial testing of 25,215 SNPs was carried out in DNA pools
of Sample Set 1 as described previously (Cargill et al., 2007).
Markers that had allelic Po0.05 were then tested for replication in
DNA pools of Sample Set 2. Replicated markers (allelic Po0.05)
were then sequentially individually genotyped in these and a third
sample set. For this report, a total of 62 SNPs were individually
genotyped in all three sample sets, 189 markers in two sample sets,
and 86 markers in one sample set. The two IFIH1 markers,
rs35667974 and rs10930046, were further genotyped in Sample
Set 4 (Supplementary Table S1 online details which SNPs were
individually genotyped in each sample set).
Genotyping
For Sample Sets 1, 2, and 3, individual genotyping was performed
using allele-specific kinetic PCR on 0.3 ng of DNA at Celera. Data
were hand curated before statistical analysis, without knowledge of
case–control status. Genotyping calls were made on 495% of
samples. Previous analyses suggest a genotyping accuracy of499%
(Cargill et al., 2007). For the fourth sample set, genotyping was
performed at a laboratory at the University of California, San
Francisco using Applied Biosystems (Foster City, CA) TaqMan assays.
Statistics
Deviation from Hardy–Weinberg equilibrium was examined in the
control samples using the exact test of Weir (1996). Allelic
association of a marker with disease status was determined by the
w2-test; a meta-analysis in all three sample sets was carried out using
fixed effects of the Mantel–Haenszel method to combine ORs across
the sample sets. P-values were two sided in all samples combined.
ORs and 95% confidence intervals were estimated from the allele or
genotype counts. Assessment of OR heterogeneity across sample sets
was carried out by the Breslow–Day test. Testing the independence
of two markers was carried out by logistical regression. The linkage
disequilibrium measure r2 was calculated from unphased data with
use of the LDMAX program in the GOLD package. Power and
sample size for an association study in a case–control study
were estimated using the program ‘‘PS: Power and Sample Size
Calculation’’ (http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/
PowerSampleSize) with the assumption of independent cases and
controls being used at a ratio of 1:1. The type I error probability
associated with the test of a null hypothesis was set at 0.05. An
uncorrected w2 statistic was used to evaluate this null hypothesis.
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